RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Systemic ANCA positive (+) vasculitides
Relapsing or refractory vasculitides, resistant to corticosteroids and reference immunosuppressant therapies
Age >18 years old
Written informed consent
Newly diagnosed patient
Patient that had never received an immunosuppressant before to treat his/her vasculitis